Cirrhosis-enriched TREM2+CD9+ scar-associated macrophages, largely originating from circulating monocytes, contribute to matrix remodeling and immune suppression; anti-TREM2 therapy paired with ICIs restored cytotoxic T-cell activity in preclinical studies (147). This evidence concerns the gene TREM2 and Cirrhosis.